Bipolar depression can be one of the most persistent and disruptive parts of bipolar disorder. At Revitalize Ketamine Clinic in Prescott Valley, we offer ketamine treatment and TMS therapy for patients exploring advanced options after prior care has not provided adequate relief.
Bipolar depression requires a different approach from unipolar depression. Treatment decisions must account for a person’s history of mania, hypomania, mixed symptoms, medication response, and current mood stability. Current bipolar-disorder guidelines recommend several established medication options before considering more specialized interventions.
Why Bipolar Depression Is Difficult to Treat
Bipolar depression can affect energy, sleep, concentration, motivation, relationships, and the ability to manage everyday responsibilities. It can also be difficult to treat because medications commonly used for unipolar depression may require added caution in bipolar disorder.
For bipolar I depression, guidelines identify options such as lithium, lamotrigine, quetiapine, and lurasidone-based regimens among first-line treatments. Antidepressant use requires individualized assessment, and antidepressant monotherapy is not recommended for bipolar I depression because of the potential for mood destabilization. (Yatham et al., 2018; Keramatian et al., 2023).
When depressive symptoms persist despite appropriate treatment, the next step is not a one-size-fits-all protocol. A comprehensive evaluation should review diagnosis, previous treatment trials, medication tolerability, psychotherapy history, substance-use concerns, medical conditions, and any current manic, hypomanic, or mixed symptoms. Understanding how to cope with bipolar disorder can be a useful starting point for patients navigating these complexities alongside their care team.
Ketamine’s Role in Bipolar Depression
IV ketamine treatment has been studied as an off-label adjunctive option for bipolar depression. Canadian treatment guidelines list intravenous racemic ketamine as a third-line adjunctive option for acute bipolar depression, reflecting both the potential for rapid symptom improvement and the need for careful clinical selection and monitoring. (Keramatian et al., 2023).
A systematic review of ketamine studies in bipolar depression found promising short-term results, but also emphasized that the evidence base remains limited, with small samples and unanswered questions about long-term effectiveness, maintenance, and safety. Mood elevation or switching appears uncommon in published studies, but it remains an important clinical consideration. (Fancy et al., 2023).
Ketamine is not FDA-approved for bipolar depression. Treatment should be considered only after a full psychiatric and medical evaluation, with close coordination with the patient’s existing prescribing and mental health providers. For more background, read where ketamine comes from and how it has been used medically.
SPRAVATO® and Bipolar Depression: Important Limits
SPRAVATO® is an esketamine nasal spray approved for adults with treatment-resistant depression and, when used with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. Its FDA-approved indications do not include bipolar depression. (Janssen Pharmaceuticals, Inc., 2025).
That distinction matters. SPRAVATO® should not be presented as an FDA-approved treatment for bipolar depression, and FDA approval for treatment-resistant depression does not establish it as appropriate for a bipolar diagnosis. The current evidence for esketamine in bipolar depression remains limited. (Rodolico et al., 2024).
Patients interested in learning more about the medication can review Revitalize’s SPRAVATO® treatment information, then discuss whether it is clinically appropriate for their diagnosis and treatment history.
TMS as a Potential Adjunct
TMS is a noninvasive treatment that uses magnetic pulses to stimulate targeted brain regions. It is FDA-cleared for treatment-resistant depression and certain other indications, but it is not FDA-cleared specifically for bipolar depression.
Research on TMS for bipolar depression is evolving. A systematic review and network meta-analysis found that some TMS protocols showed potential benefit, but the evidence remains limited and results vary by protocol. TMS should not be described as an established or guaranteed treatment for bipolar depression. (Kishi et al., 2024).
At Revitalize, TMS therapy in Flagstaff, AZ is available as part of a broader evaluation process. TMS does not involve systemic medication exposure, but people with bipolar disorder still require careful monitoring for changes in mood symptoms throughout treatment.
A Comprehensive Approach for Complex Cases
Bipolar depression rarely exists in isolation. Anxiety, trauma history, chronic pain, substance-use concerns, sleep disruption, and medication side effects can all affect treatment planning.
A comprehensive care plan may include ongoing psychiatric medication management, psychotherapy, sleep and routine stabilization, safety planning, and coordination with outside providers. For patients receiving ketamine, preparation and reflection after treatment may also be useful parts of a broader support plan.
The goal is not to chase a single intervention. It is to identify an approach that fits the person’s diagnosis, current mood state, treatment history, and safety needs.
Frequently Asked Questions
Can ketamine cause mania in people with bipolar disorder?
Mood switching appears uncommon in the limited published ketamine literature, but it can occur. Ketamine should be considered only with careful assessment, monitoring, and coordination with the patient’s prescribing provider. (Fancy et al., 2023).
Is SPRAVATO® covered by insurance for bipolar depression?
SPRAVATO® is not FDA-approved for bipolar depression. Coverage decisions vary by insurer and plan, and should not be assumed for an off-label diagnosis.
How does ketamine interact with mood stabilizers?
There is no universal answer. A provider should review all medications, medical conditions, psychiatric history, and current mood symptoms before recommending ketamine treatment. Do not start, stop, or change medication without guidance from your prescribing clinician.
How is bipolar depression treated differently from unipolar depression?
Treatment for bipolar depression requires attention to mania or hypomania history, mixed symptoms, mood stability, and medication-related switch risk. Treatments that may be appropriate for unipolar depression are not automatically appropriate for bipolar depression.
What if I am currently hypomanic, manic, or in a mixed state?
Active mania, hypomania, or mixed symptoms require prompt assessment by a qualified mental health professional. Stabilization and safety should take priority before considering treatments directed at bipolar depression.
Key Takeaways
- Bipolar depression requires individualized care that accounts for mood stability, treatment history, and the risk of mood switching.
- IV ketamine is an off-label, third-line adjunctive option in some bipolar-depression guidelines, but evidence remains limited.
- SPRAVATO® is not FDA-approved for bipolar depression.
- TMS is FDA-cleared for treatment-resistant depression, not specifically for bipolar depression.
- Advanced treatment decisions should be made through careful psychiatric evaluation and coordination with existing providers.
If bipolar depression has continued despite standard treatment, Revitalize Ketamine Clinic in Prescott Valley can help you explore whether additional evaluation may be appropriate. Call 928-493-8222 to schedule a consultation.
References
Fancy, F., et al. (2023). Ketamine for bipolar depression: An updated systematic review. Therapeutic Advances in Psychopharmacology, 13. https://doi.org/10.1177/20451253231202723
Janssen Pharmaceuticals, Inc. (2025). SPRAVATO® (esketamine) nasal spray: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Keramatian, K., et al. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344-353. https://doi.org/10.1176/appi.focus.20230009
Kishi, T., Ikuta, T., Sakuma, K., Hatano, M., Matsuda, Y., Kito, S., & Iwata, N. (2024). Repetitive transcranial magnetic stimulation for bipolar depression: A systematic review and pairwise and network meta-analysis. Molecular Psychiatry, 29, 39-42. https://doi.org/10.1038/s41380-023-02045-8
Rodolico, A., Cutrufelli, P., Di Francesco, A., et al. (2024). Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: An overview of systematic reviews with meta-analysis. Frontiers in Psychiatry, 15, 1325399. https://doi.org/10.3389/fpsyt.2024.1325399
Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy, TMS, SPRAVATO®, and medication management should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide & Crisis Lifeline or go to your nearest emergency room.